Business
RenalytixAI Forms Core Investigator Group
RenalytixAI Forms Core Investigator Group.
About this update from Renalytix Plc
[{"type":"text","content":"\n \nRNS Number : 6572T Renalytix AI PLC 22 March 2019 \n\n \nRenalytix AI plc\n(\"RenalytixAI\" or the \"Company\")\n \nRenalytixAI Forms Core Investigator Group\nfor Kidney Transplant Advanced Diagnostic Program\n \nInvestigators include leading transplant clinicians from Emory University, the University of Manitoba, the Westmead Hospital Sydney, and Icahn School of Medicine at Mount Sinai\n \nRenalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the formation of the core investigator group to support clinical and regulatory pathways for a portfolio of advanced diagnostic and prognostic solutions in kidney transplant known collectively as FractalDx. This follows the Company's announcement on January 2, 2019 that stated it had exercised its option from the Icahn School of Medicine at Mount Sinai (\"ISMMS\") for the exclusive license to technology and data underlying the FractalDx product portfolio. \n \nProducts under development from FractalDx are anticipated to be part of the extended RenalytixAI pipeline following the introduction of KidneyIntelX in 2019 for the diagnosis of fast-progressing chronic kidney disease. RenalytixAI hopes to commercialize a range of advanced diagnostic tests that are expected to aid in accurate dosing of immune-suppression therapy and in making significant improvements in the identification of and monitoring for kidney transplant rejection. \n \nThe FractalDx technology is based primarily on sequencing biomarkers from a patient's blood using widely available instrument platforms such as Illumina sequencers. \n \n\"Our hope is that FractalDx will give us the ability to tailor immunosuppressive therapy to the personal needs of the patient. The current therapeutic practice of 'one size fits all' dosing results in unnecessary complications including infection, cancers or avoidable rejections,\" said Dr. Barbara Murphy, Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai, and Chair of the Scientific Advisory Board of RenalytixAI. \"We have the technology to support development of a test that will apply personalized medicine to kidney transplant patients to guide administration of...